COMP <GO>
ARQT vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Arcutis Biotherapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ARQT 5
— ABBV 9
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: ARQT
LAST: $32.07 (+0.31%) • MKT CAP: $4.02B
options-implied-move
6.90%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARQT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARQT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.20% | 70.20% | +20.00 | ARQT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.00% | 29.00% | -32.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.16% | 3.47% | -3.63 | ABBV | /fcf-yield <GO> |
| Operating Margin | -3.30% | 24.60% | -27.90 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -4.30% | 6.90% | -11.20 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 91.30% | 8.60% | +82.70 | ARQT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.78 | 5.33 | +2.45 | ARQT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.90% | 7.40% | -0.50 | ARQT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.3 | 72.8 | -6.44 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.15 | -0.15 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 113.1x | -89.10 | ARQT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.02B | $513.86B | -$509.84B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARQT REV | ABBV REV | ARQT GROSS % | ABBV GROSS % | ARQT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $376.1M | $61.16B | 90.2% | 70.2% | -$6.3M | $17.82B |
| FY 2024 | $196.5M | $56.33B | 90.3% | 70.0% | -$112.3M | $17.83B |
| FY 2023 | $59.6M | $54.32B | 44.0% | 44.0% | -$249.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARQT // BETA 1.00
ABBV // BETA 1.15